AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.
AS1411 binds nucleolin (NCL) and is the first oligodeoxynucleotide aptamer to reach phase I and II clinical trials for the treatment of several cancers. However, the mechanisms by which AS1411 targets and kills glioma cells and tissues remain unclear. Here we report that AS1411 induces cell apoptosi...
Main Authors: | Ye Cheng, Gang Zhao, Siwen Zhang, Fares Nigim, Guangtong Zhou, Zhiyun Yu, Yang Song, Yong Chen, Yunqian Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5132312?pdf=render |
Similar Items
-
Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting
by: André Miranda, et al.
Published: (2021-02-01) -
Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
by: Sif Holmboe, et al.
Published: (2017-01-01) -
Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
by: Yuri Cho, et al.
Published: (2016-01-01) -
Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment
by: Liang X, et al.
Published: (2021-03-01) -
Bcl11b Regulates Cell Growth of Glioma
by: Chih-HsienWu, et al.
Published: (2014)